Search

Your search keyword '"Genta, F"' showing total 131 results
Start Over Author "Genta, F"
131 results on '"Genta, F"'

1. Italian Breast Cancer Adjuvant Chemo-hormone Therapy Cooperative Group Trials

Author

Boccardo, F., Rubagotti, A., Amoroso, D., Mesiti, M., Pacini, P., Gallo, L., Sismondi, P., Giai, M., Genta, F., Mustacchi, G., Agostara, B., Bolognesi, A., Villa, E., Schieppati, G., Ausili Cefaro, G. P., Bellantone, R., Farris, A., Sassi, M., Patrone, F., Schlag, P. M., editor, Senn, H.-J., editor, Diehl, V., editor, Parkin, D. M., editor, Rajewsky, M. F., editor, Rubens, R., editor, Wannenmacher, M., editor, Senn, Hans-Jörg, editor, Gelber, Richard D., editor, Goldhirsch, Aron, editor, and Thürlimann, Beat, editor

Published
1998
Full Text
View/download PDF

2. Predictors of long-term survival in patients undergoing residential cardiac rehabilitation (rCR) after transcatheter aortic valve replacement (TAVR): a multicenter retrospective study

Author

Tarro Genta, F, primary, Marcassa, C, additional, Ceresa, M, additional, Scalvini, S, additional, Dalla Vecchia, L A, additional, Bussotti, M, additional, Iannuzzi, G L, additional, Rizzo, C, additional, Pedretti, R F E, additional, Giordano, A, additional, and La Rovere, M T, additional

Published
2021
Full Text
View/download PDF

4. Residential cardiac rehabilitation (rCR) derived survival predictors in patients after transcatheter aortic valve replacement (TAVR): a retrospective multicenter study

Author

Tarro Genta, F, primary, Dalla Vecchia, L, additional, Scalvini, S, additional, Sarzi Braga, S, additional, Iannuzzi, G.L, additional, Bussotti, M, additional, Ceresa, M, additional, Rizzo, C, additional, Riboni, G, additional, Marcassa, C, additional, Giordano, A, additional, and Pedretti, R.F.E, additional

Published
2020
Full Text
View/download PDF

7. Linking the ICF codes to clinical real-ufe assessments: The challenge of the transition from theory to practice [Misure di valutazione e abbinamento dei codici ICF in medicina riabilitativa: La sfida del passaggio dalla teoria alla pratica]

Author

Giardini, A., Vitacca, M., Pedretti, R., Nardone, A., Chiovato, L., Spanevello, A., Abdo, S., Aiachini, B., Ambrosetti, M., Bazzini, G., Bianchi, F., Bianchi, L., Bruschi, C., Capirossi, C., Condello, S., Corica, G., Coma, S., Cossa, F., Cremascoli, S., De Cicco, D., Estraneo, A., Felicetti, G., Ferrari, M., Ferriero, G., Garbelli, C., Giorgi, G., Giorgi, I., La Manna, A., Lanzillo, B., Lodigiani, A., Lorenzoni, M., Lo Russo, F., Losavio, E., Manera, M. R., Mariani, P., Mazza, A., Mauri, R., Multari, V., Nicola, L., Paneroni, M., Panigazzi, M., Passantino, A., Pedretti, R. F., Piaggi, G., Pistarini, C., Pribetich, M., Rosolia, P., Sparpaglione, D., Springhetti, I., Santoro, C., Schmid, M., Genta, F. T., Terolla, C., Traversi, E., Traversoni, S., and Zaliani, A.

Subjects
Disability, Rehabilitation medicine, Chronicity, ICF, medicina riabilitativa, disabilità, cronicità
Published
2019

10. Second Blood Meal by Female Lutzomyia longipalpis:Enhancement by Oviposition and Its Effects on Digestion, Longevity, and Leishmania Infection

Author

Moraes, C. S., Aguiar-Martins, K., Bates, P. A., Dillon, R. J., Genta, F. A., Moraes, C. S., Aguiar-Martins, K., Bates, P. A., Dillon, R. J., and Genta, F. A.

Abstract

Lutzomyia longipalpis is the main vector of visceral leishmaniasis (VL) in America. Physiological and molecular mechanisms of Leishmania infection in sand flies have been studied during the first gonotrophic cycle. There are few studies about these interactions during the second gonotrophic cycle mainly because of the difficulties maintaining sand flies through sequential feeds. Here we standardized conditions to perform the second blood feed efficiently, and our results show that oviposition is an essential factor for the success of multiple feeds. We evaluated the impact of the second blood meal on longevity, protein digestion, trypsin activity, and Leishmania mexicana development within L. longipalpis gut. Mortality of blood-fed females increases after second blood meal as compared to sugar-fed females. Trypsin activity was lower during the second gonotrophic cycle. However, no difference in protein intake was observed between blood meals. There was no difference in the population size of Leishmania in the gut after both blood meals. In this work, we presented an optimized protocol for obtaining sufficient numbers of sand fly females fed on a second blood meal, and we described some physiological and parasitological aspects of the second gonotrophic cycle which might influence the vectorial competence of sand flies.

Published
2018

12. Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study

Author

Mieog, Js, Morden, Jp, Bliss, Jm, Coombes, Rc, van de Velde CJ, IES Steering Committee: Delozier, T, Veronesi, A, Vrdoljak, E, Monnier, A, Coombes, C, Nagykalnai, T, Roumen, Rm, Utracka Hutka, B, Pluzanska, A, Porpiglia, M, Genta, F, Benedetto, Chiara, Sozzani, P, Steiner, M, Rubinov, R, Leviov, M, Semiglazov, V, Fox, J, Mayordomo, Ji, Cervek, J, Sleeboom, Hp, Jassem, J, Hinton, Cp, Paulsen, Th, Guleng, Rj, Fein, L, Gutulescu, N, Florián, J, Rosso, R, Rutgers, Ej, Krzakowski, M, Pienkowski, T, Krajina, Z, Siffnerova, H, Pawlicki, M, Drosik, K, Wagnerowa, M, Brunt, M, Vukelja, S, Mitrowic, L, Cataliotti, L, Karnicka Mlodkowska, H, Bonnefoi, H, Tilch, G, Chollet, P, Patel, A, Kamby, C, Giustini, L, Acito, L, Mouridsen, H, Roche, H, De Lafontan, B, Tomczak, P, Petruzelka, L, Lortholary, A, Pacquola, Mg, Skene, A, Rici, S, Michelotti, A, Ghilezan, N, Stewart, A, Beauduin, M, Andersen, J, Vassilaros, S, Celio, L, Bajetta, E, Bastús, R, Marsland, T, Paridaens, R, Tzekova, V, Lichtenegger, W, Piersma, H, Jones, S, Holmberg, S, Verhoeven, D, Hill, A, Porcile, G, Bruno, Mf, Chernozemski, I, Coleman, R, Jadeja, J, Cohn, A, Merlano, M, Perroni, D, Di Costanzo, F, Van Bochove, A, Gerrits, Ma, Malec, V, Balil, A, Mendiola, C, Dodwell, D, Knox, R, Horgan, K, Joannides, T, Leonard, Rc, Cawthorn, Sj, Ghosh, C, Cantrell, J, Campos, D, Orti, R, Diedrich, K, Aas, H, Barnadas, A, Vila, Mm, Makris, A, Anderson, T, Chittor, S, Michel, J, Philip, P, Redmond, P, Mastboom, Wj, Nordenskjöld, B, Simmonds, P, Grieve, Rj, Tomova, A, Piot, G, Borea, G, Ucci, G, Einarsson, E, Nicholson, S, Gardiol, Ea, Kerger, J, Schlosser, J, Namer, M, Pinotti, G, Rutten, Ht, Iversen, T, Nejim, A, Dudov, A, Grundtvig, P, Lang, I, Massidda, B, Van De Velde CH, Gervasio, Mh, Tengrup, I, Tennvall, L, Goodman, S, Modgill, Vk, Vorobiof, Da, Mickiewicz, E, Chirgwin, J, Focan, C, Albin, N, Contu, Aa, Svensson, Jh, Borghede, G, Källström, Ac, Forbes, Jf, Hurtz, Hj, Tubiana Hulin, M, Viens, P, Scanni, A, Arnoldi, E, Nastasi, G, Bottini, A, Alquati, P, Muscat, V, Brincat, S, Holmen, K, Amaral, N, Moreno, I, Trask, C, Robinson, A, Mcintyre, K, Otsuka, A, Hohaus, B, Hoefig, G, Georgoulias, V, Salvagni, S, Bidin, L, Artioli, F, Engan, T, Benedikstsson, Kp, Campbell, I, Harvey, V, Zimbler, H, Mrsic Krmpotic, Z, Canon, Jl, Tchilingirov, Pv, Buser, K, Bolanca, A, Reztke, U, Rhein, U, Jouve, M, Mullins, G, Vesentini, L, Gallo, L, Merlini, L, Decensi, A, Carreca, I, Van Tienhoven, G, Börjesson, B, Hansen, J, Koza, I, Arcusa, A, Inoriza, A, Pelegri, A, Eremin, O, Modiano, Mr, Anthony, S, Donat, D, Richardet, E, Kochli, O, Zeißig, P, Gauch, G, Aabo, K, Fumoleau, P, Erdkamp, Fl, Lovén, L, Jönsson, Pe, Perren, T, Stuart, N, Galindo, E, Marek, Bj, Salmon, Jp, Dohollou, N, Thompson, R, Folco, U, Rosa, A, Tonato, M, Heijmans, Gj, Koralewski, P, Bång, H, Lescure, Ar, Carrato, A, Martin, M, Neave, F, Howell, T, Savin, M, Loesch, D, Hannois, A, Mohr, A, Laube, T, Omar, S, Bonneterre, J, Servent, V, Danese, S, Sertoli, Mr, Butzelaar, Rm, Steller, Ep, Gomez, H, Skoog, P, Alvarez, I, Aguilar, Ea, Giner, Jl, Yosef, Hm, Barrett Lee, P, Buzdar, Au, George, T, Olivaires, J, Vsianska, M, Köhler, U, Lindeløv, B, Toftdahl, Db, Nielsen, Eb, Veyret, C, Castera, D, Kerbrat, P, Vassilaros, P, Yeo, W, Boni, C, Aitini, E, Luporini, G, Herben, Mg, Espelid, H, Dahl, S, Ingvar, C, Meana, A, Pico, C, Garcia, Am, Agrawal, Rk, Gruenberg, D, Nunez de Pierro, A, Gill, G, Nogaret, Jm, Honhon, B, Wassenaar, H, Nielander, R, Warnier, P, Sessa, C, Padrik, P, Guastalla, Jp, Serin, D, Jaubert, D, Dank, M, Given, Fh, Mascia, V, De Fraia, E, Silingardi, V, Conte, Pf, Labianca, R, Tondini, C, Bagnulo, A, Gardani, G, Wils, J, Liem, G, Nuytinck, Jk, Formoe, E, Ambré, T, Alés, J, Aramburo, P, Mansi, J, Graham, J, Joffe, J, Sainsbury, J, Stone, J, Good, Rh, Cartwright, T, Werner, Id, Murray, E, Beith, J, Tigges, Fj, Bojko, P, Sandberg, E, Jensen, B, Lotz, Jp, Carney, D, Shapira, J, Neumann, A, Goldhirsch, A, Dicato, M, de Graaf, H, Maartense, E, Burghouts, J, Cassinello, J, Jones, A, Gaffney, C, Blum, R, Abdi, E, Becquart, D, Dirix, L, Janssens, J, Nmarschner, N, Blaska Jaulerry, B, Prevot, G, Mirah Lev, L, Shani, A, Baruch, Nb, Peretz, T, Gips, M, Cognetti, F, Carlini, P, Nortier, Jw, Huinink D, ten B., Roussel, Jg, Unneberg, K, Kylberg, F, Hovind, H, Nestvold, T, Fogelkvist, R, Due, J, Muller, S, Gilligan, D, Russel, S, Mcaleer, J, Yiangou, C, Foote, L, Schottstaedt, M, Holmes, Fa, Wainstein, R, Contreras, O, Martinez, J, Della Fiorentina, S, Beslija, S, Vermorken, Jb, Thirion, M, Fraikin, J, Castiglione, M, Jäger, W, Fasching, P, Fabriz, H, Neis, K, Kirschbaum, M, Labat, Jp, Dupuis, O, Bernard, J, Datchary, J, Provencal, J, Allain, P, Clerico, M, Lopez, M, Nalli, G, Aspevik, R, Fràguas, A, Curescu, S, Cuevas, Jm, Oltra, A, Bradley, C, Kapoor, R, Akbain, S, Croghan, Mk, Modiano, M, Taetle, R, Beale, P, Gobert, P, Bondue, H, Böhm, R, Møller, Ka, Brettes, Jp, Netter, G, Grogan, L, Klein, B, Botta, M, Barni, S, Van Meerwijk, I, Kåresen, R, Godes, J, Aramburo, A, Jara, C, Zanger, B, Fleagle, Jt, Greenspan, A, Marschke, R, Medgyesy, Dc, Garbo, L., CCA -Cancer Center Amsterdam, and Radiotherapy

Subjects
medicine.medical_specialty, Population, Breast Neoplasms, Disease-Free Survival, chemistry.chemical_compound, Breast cancer, Exemestane, Internal medicine, Surveys and Questionnaires, medicine, Clinical endpoint, Humans, Carpal tunnel syndrome, education, Aged, Retrospective Studies, Aged, 80 and over, education.field_of_study, business.industry, Aromatase Inhibitors, Hazard ratio, Middle Aged, medicine.disease, Carpal Tunnel Syndrome, Surgery, Musculoskeletal Abnormalities, Androstadienes, Postmenopause, Tamoxifen, Treatment Outcome, Oncology, chemistry, Hormonal therapy, Female, business, medicine.drug
Abstract

BACKGROUND: Aromatase inhibitors are more effective than is tamoxifen in prevention of breast-cancer recurrence, but at the expense of increased musculoskeletal side-effects, such as carpal tunnel syndrome. The aim of this study was to assess risk factors and the prognostic value of musculoskeletal symptoms during treatment with the steroidal aromatase inhibitor exemestane or with tamoxifen after 2-3 years of tamoxifen. METHODS: In the Intergroup Exemestane Study, postmenopausal women treated for early invasive breast cancer who remained disease free and on treatment after 2-3 years of tamoxifen were randomised to switch to exemestane or to continue tamoxifen for the remainder of the 5-year period of endocrine treatment. The primary endpoint for this retrospective analysis was occurrence of carpal tunnel syndrome and any musculoskeletal events, analysed in the safety population, which consisted of all patients who had received any trial treatment. As well as case-report forms, questionnaires were distributed retrospectively to gain more details of cases of carpal tunnel syndrome. The relation between musculoskeletal symptoms reported by 6 months from randomisation and survival from 9 months onwards was assessed by Cox proportional hazards models. The trial is registered, number ISRCTN11883920. It has completed accrual and follow-up is continuing for enrolled participants. FINDINGS: After a median follow-up of 91·0 months (IQR 83·0-99·2), carpal tunnel syndrome had been reported for 66 (2·8%) of 2319 patients in the exemestane group compared with 13 (0·6%) of 2338 in the tamoxifen group (odds ratio [OR] 5·23, 99% CI 2·39-11·49; p

Published
2012

15. Chemotherapy vs Tamoxifen vs Chemotherapy + Tamoxifen in Node-positive, Oestrogen-receptor positive Breast Cancer Patients. An update at 7 years of the 1st GROCTA Trial

Author

Boccardo, F., Rubagotti, A., Amoroso, D., Sismondi, P., Genta, F., Nenci, I., Piffanelli, A., Farris, A., Castagnetta, L., Traina, A., Cappellini, M., Pacini, P., Sassi, M., Malacarne, P., Donati, D., Mustacchi, Giorgio, Galletto, L., Schieppati, G., Villa, E., Bolognesi, A., Gallo, L., Boccardo, F., Rubagotti, A., Amoroso, D., Sismondi, P., Genta, F., Nenci, I., Piffanelli, A., Farris, A., Castagnetta, L., Traina, A., Cappellini, M., Pacini, P., Sassi, M., Malacarne, P., Donati, D., Mustacchi, Giorgio, Galletto, L., Schieppati, G., Villa, E., Bolognesi, A., and Gallo, L.

Published
1992

19. 3 cm and T4 breast cancer patients

Author

Bellino, R., Cortese, P., Danese, S., DE SANCTIS, C., Durando, A., Genta, F., Grio, Ruggero, Giardina, G., Katsaros, D., Massobrio, Marco, Richiardi, G., and Vicelli, R.

Published
2000

20. Italian Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group Trials. GROCTA Trials

Author

Boccardo, F., Alessandra RUBAGOTTI, Amoroso, D., Mesiti, M., Pacini, P., Gallo, L., Sismondi, P., Giai, M., Genta, F., Mustacchi, G., Agostara, B., Bolognesi, A., Villa, E., Schieppati, G., Ausili Cefaro, G. P., Bellantone, R., Farris, A., Sassi, M., and Patrone, F.

Subjects
Survival Rate, Clinical Trials as Topic, Hormonal, Antineoplastic Agents, Hormonal, Italy, Chemotherapy, Adjuvant, Settore MED/18 - CHIRURGIA GENERALE, Chemotherapy, Humans, Antineoplastic Agents, Breast Neoplasms, Female, Adjuvant
Abstract

The first GROCTA trial compared 5-year tamoxifen treatment to ten chemotherapy cycles in a group of 504 pre-/post-menopausal, node-positive, ER-positive breast cancer patients. This study also included an arm combining tamoxifen with chemotherapy. Fifteen-year results showed no difference between tamoxifen and tamoxifen plus chemotherapy, while both treatments were significantly superior to chemotherapy alone. A confirmatory study (GROCTA 02) was performed in 244 pre-/perimenopausal patients by comparing 5 years of tamoxifen treatment (plus 2 years of goserelin) to six CMF cycles. No difference has emerged so far between the tamoxifen and CMF arms at a median follow-up time of 62 months. Post-menopausal women were scheduled to receive 3 years of tamoxifen treatment and then to be randomly allocated to further 2 years of tamoxifen or to 2 years of low-dose aminoglutethimide (GROCTA 04B). So far 662 patients have been entered, 375 of whom have been randomized to tamoxifen (n = 188) or aminoglutethimide (n = 187). Preliminary results (median follow-up time 32 months) show no major difference in patients' outcome. A new trial (ITA trial) with a similar design but employing anastrozole in place of aminoglutethimide has been activated in 1998. The GROCTA 03 study investigated the potential superiority of alternating adjuvant chemotherapy over standard CMF. This study, which included 107 node-positive ER-negative pre-menopausal women, was prematurely closed because more patients allocated to the triple alternated chemotherapy appeared to have relapsed and died at the first interim analysis. The use of high-dose chemotherapy (HDC) was explored by the GROCTA 06 trial which included 53 patients with ten or more involved nodes and a maximum age of 55 years. These patients were scheduled to receive three standard CEF cycles followed by one cycle of HDC (cyclophosphamide 5 g/m2; etoposide 1.5 g/m2; cisplatin 150 mg/m2) without any form of bone marrow rescue. This HDC program proved to be feasible but was not superior to CMF-based chemotherapy we had previously employed in a comparable group of patients in previous GROCTA trials. These findings prompted us to explore new HDC programmes with the use of peripheral stem cell support and in addition the possible value of new drugs such as Taxol and vinorelbine. New-generation trials will also explore the value of new prognostic indicators such as tumor proliferative activity, which are prospectively used to allocate patients to different treatment options.

Published
1999

24. Potential role for gut microbiota in cell wall digestion and glucoside detoxification in Tenebrio molitor larvae

Author

Genta, F A, Dillon, R J, Terra, W R, Ferreira, C, Genta, F A, Dillon, R J, Terra, W R, and Ferreira, C

Abstract

Tenebrio molitor larvae were successfully reared free of cultivatable gut lumen bacteria, yeasts and fungi using two approaches; aseptic rearing from surface sterilized eggs and by feeding larvae with antibiotic-containing food. Insects were reared on a rich-nutrient complete diet or a nutrient-poor refractory diet. A comparison of digestive enzyme activities in germ free and conventional insects containing a gut microbiota did not reveal gross differences in enzymes that degrade cell walls from bacteria (lysozyme), fungi (chitinase and laminarinase) and plants (cellulase and licheninase). This suggested that microbial-derived enzymes are not an essential component of the digestive process in this insect. However, more detailed analysis of T molitor midgut proteins using an electrophoretic separation approach showed that some digestive enzymes were absent and others were newly expressed in microbiota-free larvae. Larvae reared in antibiotic-containing refractory wheat bran diet performed poorly in comparison with controls. The addition of saligenin, the aglycone of the plant glucoside salicin, has more deleterious effects on microbiota-free larvae than on the conventionally reared larvae, suggesting a detoxifying role of midgut microbiota. Analysis of the volatile organic compounds released from the faecal pellets of the larvae shows key differences in the profiles from conventionally reared and aseptically reared larvae. Pentadecene is a semiochemical commonly found in other beetle species. Here we demonstrate the absence of pentadecene from aseptically reared larvae in contrast to its presence in conventionally reared larvae. The results are discussed in the light of the hypothesis that microbial products play subtle roles in the life of the insect, they are involved in the digestion of refractory food, detoxification of secondary plant compounds and modify the volatile profiles of the insect host. (c) 2006 Elsevier Ltd. All rights reserved.

Published
2006

26. Endocrine therapy of breast cancer. The experience of the Italian Cooperative Group for Chemohormonal Therapy of Early Breast Cancer (GROCTA)

Author

Boccardo, Francesco, Amoroso, D, Rubagotti, Alessandra, Sismondi, P, Desanctis, C, Cappellini, M, Pacini, P, Castagnetta, L, Traina, A, Farris, A, Iacobelli, S, Mustacchi, G, Nenci, I, Villa, E, Aldrighetti, D, Mesiti, M, Schieppati, G, Giovaninetti, A, Piatto, E, Epifani, C, Scognamiglio, G, Spinelli, I, Venturini, S, Malacarne, P, Donati, D, Piano, A, Gallo, L, Rinaldi, E, Biasioli, R, Smerieri, F, Pini, M, Visca, V, Mensi, F, Scapaticci, R, Silvani, A, Benetti, Gp, Banducci, R, Scanni, A, Tomirotti, M, Bolognesi, A, Palazzotto, G, Dicarlo, A, Canaletti, R, Rodino, C, Trompeo, P, Allara, L, Marangolo, M, Cruciani, G, Saccani, F, Sassi, M, Beni, A, Gatti, C, Burani, G, Galletto, L, Genta, F, Delazzer, F, Marsilio, B, Buzzi, F, Bartolucci, R, Delia, Svanosio, M, Rolfo, F, Castagna, B, Daddato, F, Repinto, Crucitti, F, and Lombardi, C.

Published
1993

28. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, esrogen receptor-positive breast cancer patients: results of a multicentric Italian study

Author

Boccardo, Francesco, Rubagotti, Alessandra, Bruzzi, P, Cappellini, M, Isola, G, Nenci, I, Piffanelli, A, Scanni, A, Sismondi, P, Santi, L, Genta, F, Saccani, F, Sassi, M, Malacarne, P, Donati, D, Farris, A, Castagnetta, L, DI CARLO, A, Traina, A, Galletto, L, Smerieri, F, and FOR THE GROCTA, BUZZI F.

Published
1990

29. Chemotherapy (CT) vs Tamoxifen (T) vs Chemotherapy + Tamoxifen in node positive (N+) estrogen receptor positive breast cancer patients. Results of an Italian multicenter Study

Author

Boccardo, Francesco, Rubagotti, Alessandra, Bruzzi, P., Cappellini, M., Isola, G., Nenci, I., Piffanelli, A., Scanni, A., Sismondi, P., Santi, L., Genta, F., Saccani, F., Sassi, M., Malacarne, P., Donati, D., Farris, A., Castagnetta, L., Di Carlo, A., Traina, A., Galletto, L., and Buzzi, F. S. m. e. r. i. e. r. i. F.

Published
1990

31. Italian Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group Trials. GROCTA Trials

Author

Boccardo, F, Rubagotti, Alessandra, Amoroso, D, Mesiti, M, Pacini, P, Gallo, L, Sismondi, P, Giai, M, Genta, F, Mustacchi, G, Agostara, B, Bolognesi, A, Villa, E, Schieppati, G, Ausili Cefaro, Gp, Bellantone, Rocco Domenico Alfonso, Farris, Alessandra, Sassi, M, Patrone, F, Bellantone, Rocco Domenico Alfonso (ORCID:0000-0002-0844-3469), Boccardo, F, Rubagotti, Alessandra, Amoroso, D, Mesiti, M, Pacini, P, Gallo, L, Sismondi, P, Giai, M, Genta, F, Mustacchi, G, Agostara, B, Bolognesi, A, Villa, E, Schieppati, G, Ausili Cefaro, Gp, Bellantone, Rocco Domenico Alfonso, Farris, Alessandra, Sassi, M, Patrone, F, and Bellantone, Rocco Domenico Alfonso (ORCID:0000-0002-0844-3469)

Abstract

The first GROCTA trial compared 5-year tamoxifen treatment to ten chemotherapy cycles in a group of 504 pre-/post-menopausal, node-positive, ER-positive breast cancer patients. This study also included an arm combining tamoxifen with chemotherapy. Fifteen-year results showed no difference between tamoxifen and tamoxifen plus chemotherapy, while both treatments were significantly superior to chemotherapy alone. A confirmatory study (GROCTA 02) was performed in 244 pre-/perimenopausal patients by comparing 5 years of tamoxifen treatment (plus 2 years of goserelin) to six CMF cycles. No difference has emerged so far between the tamoxifen and CMF arms at a median follow-up time of 62 months. Post-menopausal women were scheduled to receive 3 years of tamoxifen treatment and then to be randomly allocated to further 2 years of tamoxifen or to 2 years of low-dose aminoglutethimide (GROCTA 04B). So far 662 patients have been entered, 375 of whom have been randomized to tamoxifen (n = 188) or aminoglutethimide (n = 187). Preliminary results (median follow-up time 32 months) show no major difference in patients' outcome. A new trial (ITA trial) with a similar design but employing anastrozole in place of aminoglutethimide has been activated in 1998. The GROCTA 03 study investigated the potential superiority of alternating adjuvant chemotherapy over standard CMF. This study, which included 107 node-positive ER-negative pre-menopausal women, was prematurely closed because more patients allocated to the triple alternated chemotherapy appeared to have relapsed and died at the first interim analysis. The use of high-dose chemotherapy (HDC) was explored by the GROCTA 06 trial which included 53 patients with ten or more involved nodes and a maximum age of 55 years. These patients were scheduled to receive three standard CEF cycles followed by one cycle of HDC (cyclophosphamide 5 g/m2; etoposide 1.5 g/m2; cisplatin 150 mg/m2) without any form of bone marrow rescue. This HDC program pro

Published
1998

34. 0-28. Adjuvant high dose chemotherapy (HD CT) without bone marrow rescue in breast cancer patients (b.c. pts) with 10 or more positive nodes (N ≥ 10): preliminary results of an Italian breast cancer adjuvant study group (GROCTA) trial

Author

Amoroso, D., primary, Boccardo, F., additional, Rubagotti, A., additional, Ballestrero, A., additional, Ferrando, F., additional, Brema, F., additional, Genta, F., additional, Sismondi, P., additional, Sertoli, M.R., additional, Rosso, R., additional, Folco, U., additional, Irtelli, L., additional, Iacobelli, S., additional, Mammoliti, S., additional, Mesiti, M., additional, Pacini, P., additional, Rinaldini, M., additional, and Patrone, F., additional

Published
1997
Full Text
View/download PDF

35. 0.31. CMF vs tamoxifen (TAM) plus goserelin (GOS) as adjuvant treatment of ER positive (+VE) preperimenopausal breast cancer patients (pts). Preliminary results of an ongoing Italian breast cancer adjuvant study group (GROCTA) trial

Author

Boccardo, F., primary, Rubagotti, A., additional, Amoroso, D., additional, Mesiti, M., additional, Geraci, O., additional, Delia, P., additional, Villa, E., additional, Aldrighetti, D., additional, Genta, F., additional, Sismondi, P., additional, Irtelli, L., additional, Donati, D., additional, Paccini, P., additional, Farris, A., additional, and Schieppati, G., additional

Published
1997
Full Text
View/download PDF

36. PP-5-5 CMF vs Tamoxifen (TAM) Plus Goserelin (GOS) as Adjuvant Treatment of ER Positive (+VE) Pre-Perimenopausal Breast Cancer Patients (PTS). Preliminary Results of an Ongoing Italian Breast Cancer Adjuvant Study Group (GROCTA) Trial

Author

Boccardo, F., primary, Rubagotti, A., additional, Amoroso, D., additional, Mesiti, M., additional, Geraci, O., additional, Delia, P., additional, Villa, E., additional, Aldrighetti, D., additional, Genta, F., additional, De Sanctis, C., additional, Irtelli, L, additional, Donati, D., additional, Pacini, P., additional, Scotto, T., additional, and Schieppati, G., additional

Published
1996
Full Text
View/download PDF

41. Axillary dissection in breast cancer patients with metastatic sentinel node: to do or not to do? Suggestions from our series.

Author

Bartolini, M., Genta, F., Biacchiardi, Chiara Perono, Zanon, E., Camanni, M., and Deltetto, F.

Abstract

Several studies have put to question and evaluated the indication and prognosis of sentinel lymph node biopsy (SNLB) as sole treatment in human breast cancer. We reviewed 1588 patients who underwent axillary surgery. In 239 patients, axillary lymph node dissection (ALND) was performed following positive fine needle aspiration cytology (FNAC), and, in 299 cases, ALND was executed after positive SNLB. The most dramatic result from our data is that patients with either micrometastasis of the sentinel lymph node (SLN) or only metastatic SLN have, respectively, an 84.5% and a 75.0% chance of having no other nodal involvement. We believe a more refined patient selection is neccessary when considering ALND. Where the primary tumor is larger than 5 cm, where radio or adjuvant therapies are not indicated, in cases of FNAC+ nodes, and in cases presenting more than one metastatic sentinel node, we prefer to carry out ALND. Having thus said, however, our data suggests that it is wise not to perform ALND in almost all cases presenting positive SLNs. [ABSTRACT FROM AUTHOR]

Published
2011

42. Obstetric complications and schizophrenia. A case-control study.

Author

Günther-Genta, Flavia, Bovet, Pierre, Hohlfeld, Patrick, Günther-Genta, F, Bovet, P, and Hohlfeld, P

Subjects
PEOPLE with schizophrenia, SCHIZOPHRENIA, ASPHYXIA neonatorum, HOSPITAL maternity services, PEOPLE with mental illness, OBSTETRICS, BIRTH order, BRAIN damage, LABOR complications (Obstetrics), PSYCHOLOGICAL tests, PSYCHOLOGY, SEASONS, SEX distribution, WORK environment, CASE-control method, DISEASE complications
Abstract

Schizophrenics have been repeatedly found to experience more obstetric complications (OCs) at birth. The meaning of such a finding is debated, and the aim of this study is to contribute to the understanding of OCs' aetiological role in schizophrenia. We compared a group of schizophrenic patients with their siblings and controls, on the basis of obstetric files stemming from the same University Hospital Maternity Ward. Schizophrenic patients had more frequent umbilical cord complications and atypical presentations, as well as higher scores on a scale measuring OCs linked to possible neonatal asphyxia. [ABSTRACT FROM AUTHOR]

Published
1994
Full Text
View/download PDF

45. Analisi delle complicanze del trattamento del CIS nell’ambito dello studio multicentrico italiano sulla valutazione delle complicanze del trattamento del cervico-carcinoma

Author

Zola, P, Rumore, A, Genta, F, Preve, C, Maggi, R, Franchi, Massimo Piergiuseppe, Pozzi, M, Prati, A, Bianchi, A, Maggino, T, and Sismondi, P.

Subjects
Analisi delle complicanze del trattamento del CIS nell’ambito dello studio multicentrico italiano sulla valutazione delle complicanze del trattamento del cervico-carcinoma
Published
1989

47. Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma

Author

Arts, H. J., Katsaros, D., Elisabeth de Vries, Massobrio, M., Genta, F., Danese, S., Arisio, R., Scheper, R. J., Kool, M., Scheffer, G. L., Willemse, P. H., Ate van der Zee, Albert Suurmeijer, Targeted Gynaecologic Oncology (TARGON), Guided Treatment in Optimal Selected Cancer Patients (GUTS), and Other departments

Subjects
Survival Rate, ATP-Binding Cassette Transporters/chemistry, Humans, ATP Binding Cassette Transporter, Subfamily B, Member 1/analysis, Female, Multidrug Resistance-Associated Proteins, Ovarian Neoplasms/chemistry, Vault Ribonucleoprotein Particles/chemistry, Prognosis, Immunohistochemistry, Drug Resistance, Multiple, Neoplasm Proteins/chemistry
Abstract

Intrinsic and/or acquired resistance to chemotherapy is the major obstacle to overcome in the treatment of patients with ovarian carcinoma. The aim of the present study was to investigate the prognostic value of drug resistance-associated proteins P-glycoprotein (P-gp), multidrug resistance-associated protein 1 (MRP1), canalicular multispecific organic anion transporter (c-MOAT/MRP2), and lung resistance protein (LRP) in ovarian carcinoma. Expression of P-gp, MRP1, MRP2, and LRP was determined by immunohistochemistry of frozen tissue sections of 115 ovarian carcinoma patients and related to clinicopathological factors, response to chemotherapy, and progression-free survival. P-gp expression was observed in 20 of 115 (17%), MRP1 in 51 (34%), MRP2 in 19 (16%), and LRP in 85 (74%) tumors. Expression of MRP1 was related to MRP2 (P

Catalog

Books, media, physical & digital resources
See catalog results